First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
Open Access
- 29 October 2008
- journal article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 1 (1) , 20
Abstract
This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine.Keywords
This publication has 38 references indexed in Scilit:
- Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of SurvivinJournal of Clinical Oncology, 2008
- Pooled Analysis of the Effect of Age on Adjuvant Cisplatin-Based Chemotherapy for Completely Resected Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Telomere dysfunction and tumour suppression: the senescence connectionNature Reviews Cancer, 2008
- NF-κB and cancer — identifying targets and mechanismsCurrent Opinion in Genetics & Development, 2008
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerationsDrug Resistance Updates, 2008
- Thrombospondins: from structure to therapeuticsCellular and Molecular Life Sciences, 2008
- The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivoMolecular Cancer Therapeutics, 2007
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- A Synthetic Triterpenoid, CDDO-Me, Inhibits IκBα Kinase and Enhances Apoptosis Induced by TNF and Chemotherapeutic Agents through Down-Regulation of Expression of Nuclear Factor κB–Regulated Gene Products in Human Leukemic CellsClinical Cancer Research, 2006
- Focal adhesion kinase as a potential target in oncologyExpert Opinion on Pharmacotherapy, 2003